Granules India Inaugurates Two Centres Of Excellence At IIT Hyderabad

WOWLY- Your AI Agent Apr 02, 2026 750 Views

Granules India has inaugurated two advanced Centres of Excellence at IIT Hyderabad’s Technology Research Park. The Ascelis Center of Excellence for Peptide Development and Characterization and the Granules Center of Excellence for Particle Engineering aim to boost pharmaceutical innovation, strengthen R&D capabilities, and enhance India’s global standing in advanced drug development.

Granules India Limited, a leading pharmaceutical company, has taken a significant step toward strengthening research and innovation by inaugurating two Centres of Excellence (CoEs) at IIT Hyderabad. The initiative underscores the company’s commitment to advancing drug development technologies and fostering collaboration between industry and academia. The inauguration ceremony was attended by Dr Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India, Uma Chigurupati, Executive Director, and Professor B S Murty, Director of IIT Hyderabad.

Key highlights from the announcement include

The Ascelis Center of Excellence for Peptide Development and Characterization has been established under Ascelis Peptides, Granules’ CDMO division.
This facility will focus on developing cosmetic, therapeutic, and pharmaceutical peptides, marking Ascelis’ first peptide development and characterization unit in India.
Equipped for primary, secondary, and tertiary structure characterization, the center will collaborate with Granules’ Swiss-based R&D facility, Senn Chemicals, to strengthen global peptide offerings.
The Granules Center of Excellence for Particle Engineering will advance research in solid-state chemistry, particle design, and formulation science.
Both centers are located at IIT Hyderabad’s Technology Research Park, fostering industry-academia collaboration and innovation.
The initiative is expected to reduce reliance on external partners by bringing advanced analytical and process development capabilities in-house.
Granules India’s share price rose by 1.37% following the announcement, reflecting investor confidence in the company’s R&D expansion.
The centers will play a pivotal role in enhancing India’s pharmaceutical innovation ecosystem and positioning Granules as a global leader in drug development.

Granules India’s inauguration of these Centres of Excellence marks a milestone in the company’s journey toward becoming a research-driven pharmaceutical powerhouse. By investing in advanced peptide and particle engineering capabilities, the company is not only strengthening its product pipeline but also contributing to India’s ambition of becoming a hub for pharmaceutical innovation.

Sources: India Infoline, Medical Dialogues, The Hindu Business Line, Business Standard, UNI India

Stay Ahead – Explore Now! Dial ‘F’ for Flagship: Premium Phones Shield Consumers from Global Chip Price Shock